Comparative Pharmacology
Head-to-head clinical analysis: AXIRON versus DELATESTRYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXIRON versus DELATESTRYL.
AXIRON vs DELATESTRYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; binds to androgen receptors, modulating gene expression and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
Testosterone ester; binds to androgen receptors, activating gene transcription and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
One or two pump actuations (30 mg per actuation) applied to the axilla once daily; dose range 30-90 mg daily.
50 to 200 mg intramuscularly every 2 to 4 weeks.
None Documented
None Documented
The terminal elimination half-life of testosterone is approximately 10-100 minutes after intravenous injection, but for Axiron (testosterone topical solution), the apparent half-life is about 1-2 hours due to continued absorption from the skin and distribution/elimination. Clinically, steady state is achieved after about 2 weeks of daily application.
8 days (terminal); requires 5-6 weeks to reach steady state with weekly dosing
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (about 90%) and about 6% in feces via bile. Approximately 90% of a dose is excreted in urine, with the remainder in feces.
Urinary (90% as glucuronide and sulfate conjugates, 5% as unchanged drug); fecal (5%)
Category C
Category C
Androgen
Androgen